NGEN
Income statement / Annual
Last year (2025), NervGen Pharma Corp's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, NervGen Pharma Corp's net income was -$44.12 M.
See NervGen Pharma Corp,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$83.74 K
|
$145.01 K
|
$114.10 K
|
$42.95 K
|
$39.73 K
|
$39.26 K
|
$19.70 K
|
$0.00
|
| Gross Profit |
$0.00
|
-$83.74 K
|
-$145.01 K
|
-$114.10 K
|
-$42.95 K
|
-$39.73 K
|
-$39.26 K
|
-$19.70 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$13.91 M
|
$15.66 M
|
$8.00 M
|
$16.43 M
|
$6.88 M
|
$6.14 M
|
$6.62 M
|
$777.93 K
|
$0.00
|
| General & Administrative Expenses |
$11.17 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.17 M
|
$9.17 M
|
$9.63 M
|
$6.28 M
|
$5.98 M
|
$5.04 M
|
$3.47 M
|
$556.55 K
|
$11.99 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$25.08 M
|
$24.83 M
|
$17.63 M
|
$22.71 M
|
$12.87 M
|
$11.18 M
|
$10.09 M
|
$1.33 M
|
$11.99 K
|
| Cost And Expenses |
$25.08 M
|
$24.92 M
|
$17.78 M
|
$22.82 M
|
$12.91 M
|
$11.22 M
|
$10.13 M
|
$1.35 M
|
$11.99 K
|
| Interest Income |
$333.42 K
|
$812.07 K
|
$550.12 K
|
$199.62 K
|
$29.64 K
|
$18.89 K
|
$101.52 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$510.07 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$55.80 K
|
$83.74 K
|
$145.01 K
|
$114.10 K
|
$42.95 K
|
$39.73 K
|
$39.26 K
|
$19.70 K
|
$0.00
|
| EBITDA |
-$5.65 M |
-$23.91 M |
-$22.24 M |
-$19.92 M |
-$12.78 M |
-$11.17 M |
-$9.99 M |
-$1.33 M |
-$11.99 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$19.04 M
|
$925.48 K
|
-$4.61 M
|
$2.28 M
|
$85.29 K
|
$9.76 K
|
$101.52 K
|
$0.00
|
$0.00
|
| Income Before Tax |
-$44.12 M
|
-$23.99 M
|
-$22.38 M
|
-$20.54 M
|
-$12.82 M
|
-$11.21 M
|
-$10.03 M
|
-$1.35 M
|
-$11.99 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$44.12 M
|
-$23.99 M
|
-$22.38 M
|
-$20.54 M
|
-$12.82 M
|
-$11.21 M
|
-$10.03 M
|
-$1.35 M
|
-$11.99 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.61 |
-0.36 |
-0.37 |
-0.39 |
-0.33 |
-0.34 |
-0.39 |
-0.0497 |
0.0004 |
| EPS Diluted |
-0.61 |
-0.36 |
-0.37 |
-0.39 |
-0.33 |
-0.34 |
-0.39 |
-0.0497 |
0.0004 |
| Weighted Average Shares Out |
$72.33 M
|
$67.32 M
|
$59.29 M
|
$52.65 M
|
$39.29 M
|
$32.11 M
|
$25.90 M
|
$27.20 M
|
$27.20 M
|
| Weighted Average Shares Out Diluted |
$72.33 M
|
$67.32 M
|
$59.29 M
|
$52.65 M
|
$39.29 M
|
$32.11 M
|
$25.90 M
|
$27.20 M
|
$27.20 M
|
| Link |
|
|
|
|
|
|
|
|
|
